Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selpercatinib to Enhance RAI Avidity in Children, Adolescents, and Young Adults With Newly Diagnosed Differentiated Thyroid Cancers Harboring RET Fusions
NCT06458036Phase 2Recruiting
- Sponsor
- Children's Hospital of Philadelphia
- Start
- Jul 2024
- Primary completion
- Nov 2030
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of selpercatinib in differentiated thyroid cancer (DTC), sponsored by Children's Hospital of Philadelphia. Started Jul 2024; status: recruiting.
02
Drugs
selpercatinib
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT06458036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06458036.